Investor Overview

Corporate Profile
Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$7.69
Change (%) Stock is Down 0.27 (3.39%)
Volume375,863
Data as of 02/26/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
02/12/15Verastem Receives Orphan Drug Designation from FDA for VS-5584 in Mesothelioma
BOSTON--(BUSINESS WIRE)--Feb. 12, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that VS-5584 has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma. The designation was created to encourage the development of drugs that may provide significant benefit to patients suffering from ... 
Printer Friendly Version
02/05/15Verastem Announces the Grant of Inducement Awards
BOSTON--(BUSINESS WIRE)--Feb. 5, 2015-- Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that on February 2, 2015, the Company granted stock options to seven new employees to purchase an aggregate of 210,000 shares of common stock. The stock options were granted as inducements material to the new employees entering into employment with Verastem pursuant to N... 
Printer Friendly Version
02/03/15Verastem to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Feb. 3, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will present at the following upcoming investor conferences: 17th Annual BIO CEO & Investor Conference on Tuesday, February 10 at 1:30 p.m. ET at the Waldorf Astoria Hotel in New York City Le... 
Printer Friendly Version
01/29/15Verastem Announces Closing of $54 Million Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
BOSTON--(BUSINESS WIRE)--Jan. 29, 2015-- Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the closing of the previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,087,500 shares of common stock, at the public offering price of $6.50 per share. The exercise o... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.